Gene mutation ‘hotspots’ linked to better breast cancer outcomes
Kataegis is a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome. The anomaly was previously found in some cancers, but it has been unclear what role kataegis plays in tumor development and patient outcomes. Using a database of human tumor genomic data, researchers at the University of California San Diego School of Medicine and Moores Cancer Center have discovered that kataegis is actually a positive marker in breast cancer — patients with these mutation hotspots have less invasive tumors and better prognoses.
The study, published June 30 in Cell Reports, also suggests kataegis status could help doctors determine the treatment options that might work best for patients with the mutation pattern.
"We don't know what causes kataegis, and before this study not much was known about its functional importance at the molecular or clinical level," said senior author Kelly Frazer, PhD, professor of pediatrics and director of the Institute for Genomic Medicine at UC San Diego School of Medicine and Moores Cancer Center. "We've now found that kataegis is associated with a good prognosis for patients with breast cancer."
Kataegis occurs in approximately 55 percent of breast cancers. To determine the role of this phenomenon in patient outcomes, Frazer and her team studied human breast cancer data available from The Cancer Genome Atlas (TCGA), the National Institutes of Health's database of genomic information from more than 15,000 human tumors representing many cancer types. The Frazer team established the kataegis status of 97 breast tumors and then paired this information with patient data, such as age at diagnosis, treatment and outcome. They also looked at an additional 412 human breast cancers for which they predicted kataegis status.
The researchers found several different clinical factors associated with kataegis. These mutation hotspots were more common in breast cancer patients diagnosed at a later age, and patients with HER2-positive and high-grade tumors.
What's more, the presence of kataegis was a marker for good prognosis. Kataegis on chromosome 17 and 22 in particular were associated with low tumor invasiveness. And finally, although causes of death for patients in the TCGA database are not known, patients without kataegis tended to die younger (median age 47 years old) than patients with kataegis (median age 78 years old).
In a finding that helps explain kataegis' beneficial effect, the researchers noted that genes located near kataegis hotspots were less likely to behave abnormally than genes located further away in the genome.
"We think kataegis mutations are dampening the abnormal expression of neighboring genes that might otherwise contribute to tumor development and invasiveness," said Matteo D'Antonio, PhD, a postdoctoral researcher in Frazer's lab and first author of the study.
Besides providing a more promising prognosis, Frazer said kataegis status might also be helpful in determining a patient's treatment options. The researchers confirmed that tumors with kataegis have high levels of human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers can typically be treated with HER2-targeted therapies, meaning the prognosis for this tumor type is relatively good.
In addition, the researchers found that tumors with kataegis have elevated levels of PLAC1, a gene that encodes a molecule that is an immunotherapy target in gastric cancer. Immunotherapy is an approach that boosts a patient's own immune system to better fight tumors while leaving healthy tissues alone. Tumors with kataegis on chromosome 8 also tended to have lower gene activity involved in resistance to the anti-leukemia drug imatinib, also known as Gleevec.
There's a long way to go before kataegis status could be used in the clinic, Frazer said. However, using genomic data similar to that found in this study, clinicians at Moores Cancer Center at UC San Diego Health have already begun tailoring cancer treatments to individual patients. Sometimes these treatments options include new approaches being tested in clinical trials, such as immunotherapies. As the only National Cancer Institute-designated Comprehensive Cancer Center in San Diego, Moores Cancer Center participates in more than 170 clinical trials for novel therapies.
Additional co-authors of this study include Pablo Tamayo and Jill P. Mesirov, UC San Diego.